Sitagliptin is a first-in-class DPP-4 inhibitor launched in 2006 for T2D through its effect to increase incretin levels of GLP-1 and GIP, which increase insulin secretion and decrease gastric emptying. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.